Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience

Urology

Volumn 59, Issue 2, 2002, Pages 227-231

  Pansadoro, Vito ^a   Emiliozzi, Paolo ^a,b   De Paula, Francesco ^a   Scarpone, Paolo ^a   Pansadoro, Alberto ^a   Sternberg, Cora N ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Vincenzo Pansadoro Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; CHEMOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 0036169580     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01603-X     Document Type: Article

References (24)

1. Bacillus Calmette Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder; long term results
2. The role of radical cystectomy in the management of high grade superficial bladder cancer
3. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder
4. Radical cystectomy-often too late?
5. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder
6. Management of stage T1 superficial bladder cancer with intravesical Bacillus Calmette-Guérin therapy
7. Long term results of intravesical therapy for superficial bladder cancer
8. Intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder
9. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer; ten-year follow-up of a prospective randomized trial
10. Bacillus Calmette-Guérin immunotherapy; techniques and results
11. A 12 versus 6-week course of bacillus Calmette-Guérin prophylaxis for the treatment of high risk superficial bladder cancer
12. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder; a randomized Southwest Oncology Group Study
13. Intravesical bacillus Calmette-Guérin in stage T1, grade 3 bladder cancer therapy; a 7-year follow-up
14. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin
15. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumours; recurrence, progression and success
16. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder
17. Management of high grade superficial bladder cancer; role of BCG
18. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder
19. Intravesical BCG instillations in patients with carcinoma in situ and pT1G3 transitional cell carcinoma of the bladder
20. The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer
21. Five-year results of a phase II study with low-dose bacille Calmette-Guérin therapy in high-risk superficial bladder cancer
22. T1 G3 bladder tumors; the respective role of BCG and cystectomy
23. The value of conservative treatment in G3T1 bladder tumours
24. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder